Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Joshua Schafer is CCO & EVP, Bus. Development at Zevra Therapeutics. OQRO lists 1 transaction filed with the SEC under this name, the latest on Feb 14, 2025, each linked to the official Form 4.
CCO & EVP, Bus. Development
Disclosures on record
1
Companies involved
1
As of the latest filing on , Joshua Schafer reported holding 29,486 shares of Zevra Therapeutics (ZVRA), worth about $277K at the last close of $9 (Nov 17, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Zevra Therapeutics ZVRA | 29,486 | 29K direct | $9 | $277K | Feb 13, 2025 |
Is this Joshua Schafer’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Feb 13, 2025Sold~$83Kdisclosed Feb 14
DetailsOfficial recordJoshua Schafer bought shares on the open market in 2023, and has not bought since 2023. Sales in 1 of the 4 years since 2023.
Joshua Schafer reported 3 open-market purchases and 1 sale since 2023; purchases in 2023.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $83K1×1 trade |
| 2023 | $17K3×3 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Joshua Schafer reported 3 open-market purchases and 1 sale here, 2023 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Feb 13, 2025, Joshua Schafer reported holding 29,486 shares of Zevra Therapeutics (ZVRA). At the last close of $9 on Nov 17, 2026, that is about $277K. This is the stake disclosed in filings, not a net worth.
Joshua Schafer bought shares on the open market in 2023, and has not bought since 2023. Sales in 1 of the 4 years since 2023.
In SEC filings since 2023: the latest open-market purchase is from 2023; the latest open-market sale is from 2025.
Zevra Therapeutics (ZVRA), from 2023 to 2025: 3 purchases and 1 sale.